跳至主要内容
临床试验/NL-OMON52496
NL-OMON52496招募中不适用

A combination of pre-screening for DPD deficiency by genotyping/phenotyping methods and pharmacokinetics-guided dosing of 5-FU for precision treatment to prevent severe toxicity in gastrointestinal cancer patients. - DPD guided 5FU precision treatment in GI cancer

Isala Klinieken0 个研究点目标入组 75 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
75

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • age 18 years and older
  • histological proof of gastro-intestinal cancer
  • patient is considered for treatment with capecitabine or 5-FU
  • acceptable safety laboratory values
  • ECOG performance status 0-2
  • able and willing to give written informed consent
  • able and willing to undergo blood sampling for DPYD genotyping, DPD
  • phenotyping and pharmacokinetic analysis

排除标准

  • symptomatic or uncontrolled central nervous system metastases
  • patient who cannot submit itself to the formal follow-up for psychological,
  • social, family or geographical reasons
  • women who are pregnant or breast-feeding
  • women not consenting to use adequate contraceptive precautions during the
  • significant serious pathology or any instable medical condition (cardiac
  • pathology uncontrolled, myocardial infarction within 6 months before enrolment,
  • systemic active uncontrolled infection, cirrhosis (Child-Pugh score C), renal
  • failure (GFR < 20 ml/min))
  • any investigational agent within 4 weeks before enrolment
  • cimetidine or sorivudine use (due to drug-drug interactions with
  • 5-fluorouracil and capecitabine)

研究者

发起方
Isala Klinieken

相似试验

A combination of pre-screening for DPD deficiency by... | 临床试验